CN103191386B - Medicament for treating chronic hepatitis B - Google Patents
Medicament for treating chronic hepatitis B Download PDFInfo
- Publication number
- CN103191386B CN103191386B CN201310108674.9A CN201310108674A CN103191386B CN 103191386 B CN103191386 B CN 103191386B CN 201310108674 A CN201310108674 A CN 201310108674A CN 103191386 B CN103191386 B CN 103191386B
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- radix
- medicament
- folium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicament for treating chronic hepatitis B. The medicament is prepared from the following materials in parts by weight: 5 to 10 parts of figwort, 10 to 20 parts of dried ginger, 20 to 30 parts of dogwood, 10 to 20 parts of platycodon grandiflorum, 15 to 25 parts of coptis, 5 to 15 parts of chrysanthemum, 10 to 30 parts of solidago, 1 to 15 parts of henbane, 10 to 20 parts of ephedra, 15 to 30 parts of pyrrosia, 20 to 30 parts of giant knotweed, 1 to 20 parts of morinda officinalis, 1 to 20 parts of celandine, 10 to 25 parts of lalang grass rhizome, 10 to 30 parts of cocklebur fruit, 1 to 20 parts of emblic leafflower fruit, 15 to 20 parts of murraya paniculata, 10 to 20 parts of semen pharbitidis, 15 to 20 parts of inula herb, 15 to 30 parts of glabrous sarcandra herb, 10 to 20 parts of Chinese clinopodium herb, 10 to 25 parts of senna leaf, 5 to 15 parts of aleppo avens, 1 to 20 parts of uniflower swisscentaury root, 15 to 25 parts of dahurian rhododendron leaf, 15 to 25 parts of potentilla discolor, 10 to 20 parts of physalis permviana, 15 to 25 parts of root bark of white mulberry, 20 to 30 parts of lindley eupatorium herb, 1 to 20 parts of curcuma and 10 to 25 parts of peach seeds. All components of the medicament for treating the chronic hepatitis B are natural materials, so the medicament is high in safety, definite in treatment effect and suitable to be clinically popularized in a large scale.
Description
Technical field
The present invention relates to field of medicaments, relate in particular to a kind of medicament for the treatment of chronic hepatitis B.
Background technology
Hepatitis B virus test positive, the course of disease exceedes half a year or indefinite and clinical have chronic hepatitis shower all diagnosable for chronic viral hepatitis B date of the onset.Clinical manifestation is: weak, sitophobia, feel sick, the symptom such as abdominal distention, hepatalgia.Hepatomegaly, quality is moderate hardness, has light tenderness.The state of an illness can be with chronic hepatopathy face, spider angioma, liver palm, splenomegaly compared with severe one, liver function can time have an abnormal or persistent anomaly.At present chronic hepatitis B and be the trend rising year by year, therefore needs to treat the medicine of chronic hepatitis B.
Summary of the invention
The object of this invention is to provide a kind of medicament for the treatment of chronic hepatitis B.
In order to realize object of the present invention, the invention provides a kind of medicament for the treatment of chronic hepatitis B, it is to be made by the material of following weight proportioning: Radix Scrophulariae 5-10 part, Rhizoma Zingiberis 10-20 part, Fructus Corni 20-30 part, Radix Platycodonis 10-20 part, Rhizoma Coptidis 15-25 part, Flos Chrysanthemi 5-15 part, Herba Solidaginis 10-30 part, Semen Hyoscyami 1-15 part, Herba Ephedrae 10-20 part, Folium Pyrrosiae 15-30 part, Rhizoma Polygoni Cuspidati 20-30 part, Radix Morindae Officinalis 1-20 part, Herba Chelidonii 1-20 part, Rhizoma Imperatae 10-25 part, Fructus Xanthii 10-30 part, Fructus Phyllanthi 1-20 part, Folium Et Cacumen Murrayae 15-20 part, Semen Pharbitidis 10-20 part, Herba Inulae 15-20 part, Herba Sarcandrae 15-30 part, Herba Clinopodii 10-20 part, Folium Sennae 10-25 part, Radix seu Herba Gei aleppici 5-15 part, Radix Rhapontici 1-20 part, Folium Rhododendri Daurici 15-25 part, Herba Potentillae Discoloris 15-25 part, Calyx Seu Fructus Physalis 10-20 part, Cortex Mori 15-25 part, Herba Eupatorii Lindleyani 20-30 part, Radix Curcumae 1-20 part and Semen Persicae 10-25 part.
Preferably, the medicament for the treatment of chronic hepatitis B of the present invention is to be made by the material of following weight proportioning: 7 parts of Radix Scrophulariaes, 13 parts of Rhizoma Zingiberiss, 22 parts of Fructus Corni, 15 parts of Radix Platycodoniss, 21 parts of Rhizoma Coptidis, 13 parts of Flos Chrysanthemis, 28 parts of Herba Solidaginiss, 11 parts of Semen Hyoscyamis, 17 parts, Herba Ephedrae, 24 parts of Folium Pyrrosiaes, 27 parts of Rhizoma Polygoni Cuspidati, 18 parts of Radix Morindae Officinaliss, 17 parts of Herba Chelidoniis, 23 parts of Rhizoma Imperataes, 21 parts of Fructus Xanthii, 16 parts of Fructus Phyllanthis, 16 parts of Folium Et Cacumen Murrayae, 17 parts of Semen Pharbitidiss, 19 parts of Herba Inulae, 15 parts of Herba Sarcandraes, 14 parts of Herba Clinopodii, 21 parts of Folium Sennae, 11 parts of Radix seu Herba Gei aleppici, 13 parts of Radix Rhapontici, 23 parts of Folium Rhododendri Daurici, 24 parts of Herba Potentillae Discoloris, 14 parts of Calyx Seu Fructus Physaliss, 25 parts of Cortex Mori, 26 parts of Herba Eupatorii Lindleyanis, 24 parts, 16 parts of Radix Curcumaes and Semen Persicae.
More preferably, described medicament can be tablet, dispersible tablet, capsule or decoction.
Whole compositions of the medicament for the treatment of chronic hepatitis B of the present invention are all natural materials, and safety is better, and curative effect is clear and definite, are suitable for large-scale promotion clinically.
The specific embodiment
Below by embodiment, further illustrate the present invention.It should be understood that embodiments of the invention are for the present invention rather than limitation of the present invention are described.The simple modifications that essence according to the present invention is carried out the present invention all belongs to the scope of protection of present invention.Except as otherwise noted, the percent otherwise in the present invention is percetage by weight.
Embodiment decoction of the present invention
Take 7 grams of Radix Scrophulariaes, 13 grams of Rhizoma Zingiberiss, 22 grams of Fructus Corni, 15 grams of Radix Platycodoniss, 21 grams of Rhizoma Coptidis, 13 grams of Flos Chrysanthemis, 28 grams of Herba Solidaginiss, 11 grams of Semen Hyoscyamis, 17 grams, Herba Ephedrae, 24 grams of Folium Pyrrosiaes, 27 grams of Rhizoma Polygoni Cuspidati, 18 grams of Radix Morindae Officinaliss, 17 grams of Herba Chelidoniis, 23 grams of Rhizoma Imperataes, 21 grams of Fructus Xanthii, 16 grams of Fructus Phyllanthis, 16 grams of Folium Et Cacumen Murrayae, 17 grams of Semen Pharbitidiss, 19 grams of Herba Inulae, 15 grams of Herba Sarcandraes, 14 grams of Herba Clinopodii, 21 grams of Folium Sennae, 11 grams of Radix seu Herba Gei aleppici, 13 grams of Radix Rhapontici, 23 grams of Folium Rhododendri Daurici, 24 grams of Herba Potentillae Discoloris, 14 grams of Calyx Seu Fructus Physaliss, 25 grams of Cortex Mori, 26 grams of Herba Eupatorii Lindleyanis, 24 grams, 16 grams of Radix Curcumaes and Semen Persicae, add 2000 milliliters, water, in the flask that condensing tube is housed, at 80 ℃, heat 4 hours, filter.Filtrate is concentrated into 600 milliliters, obtains decoction of the present invention.
Experimental example
Inclusive criteria
1. meet < < hepatitis B Preclinic and clinic > > in 2000 (Luo Kangxian. hepatitis B Preclinic and clinic [M] .3 version. Beijing: People's Health Publisher, 2005:245-246.) in the diagnostic criteria of CHB.②HBsAg(+)、HBeAg(+)、HBV-DNA＞105cps·/mL。3. ALT is 2 times of normal value.4. this is treated in first 1 month and is not used other antiviral drugs.
Exclusion standard
1. get rid of and merge hepatitis A, hepatitis C, hepatitis D, hepatitis E person; 2. get rid of and be associated with other liver patients such as alcoholic liver disease, autoimmune liver disease; 3. get rid of doubtful hepatocarcinoma person; 4. get rid of at this and treat and in first 6 months, accept interferon, immunomodulator therapist.
Choose patient's 50 examples that meet above-mentioned standard, wherein male's 25 examples, women's 25 examples.Age 18-48 year, average 33.5 years old, course of disease March-6 year.
Therapeutic scheme
With in embodiment 1 preparation decoction treat.Take each 90 milliliters every day 2 times.Be 1 course for the treatment of half a year.
Criterion of therapeutical effect
With reference to < < viral hepatitis, prevent and treat scheme > > (Liu Yuhong, the refined modified ease powder associating of Liu Feng diammonium glycyrrhizinate treatment chronic hepatitis B life quality is observed [J]. modern hospital, 2010,10 (10): 21-23.) draft efficacy assessment standard.Effective: clinical symptoms is obviously improved or disappeared, ALT and total bilirubin (TBiL) are down to normal level, and serum HBV-DNA turns out cloudy, the anti-HBe serum conversion of HBeAg/.Effective: clinical symptoms is clearly better, HBV-DNA turns out cloudy, and the anti-HBe serum of HBeAg/ is not changed, and ALT and total bilirubin (TBiL) are down to normally.Invalid: clinical symptoms is not improved, even aggravation.
The result for the treatment of:
After the treatment of 1 course for the treatment of, find that all patients all meet effective standard.And in therapeutic process, do not observe obvious untoward reaction.
Claims (2)
1. treat the medicament of chronic hepatitis B for one kind, it is characterized in that, it is to be made by the material of following weight proportioning: Radix Scrophulariae 5-10 part, Rhizoma Zingiberis 10-20 part, Fructus Corni 20-30 part, Radix Platycodonis 10-20 part, Rhizoma Coptidis 15-25 part, Flos Chrysanthemi 5-15 part, Herba Solidaginis 10-30 part, Semen Hyoscyami 1-15 part, Herba Ephedrae 10-20 part, Folium Pyrrosiae 15-30 part, Rhizoma Polygoni Cuspidati 20-30 part, Radix Morindae Officinalis 1-20 part, Herba Chelidonii 1-20 part, Rhizoma Imperatae 10-25 part, Fructus Xanthii 10-30 part, Fructus Phyllanthi 1-20 part, Folium Et Cacumen Murrayae 15-20 part, Semen Pharbitidis 10-20 part, Herba Inulae 15-20 part, Herba Sarcandrae 15-30 part, Herba Clinopodii 10-20 part, Folium Sennae 10-25 part, Radix seu Herba Gei aleppici 5-15 part, Radix Rhapontici 1-20 part, Folium Rhododendri Daurici 15-25 part, Herba Potentillae Discoloris 15-25 part, Calyx Seu Fructus Physalis 10-20 part, Cortex Mori 15-25 part, Herba Eupatorii Lindleyani 20-30 part, Radix Curcumae 1-20 part and Semen Persicae 10-25 part.
2. the medicament for the treatment of chronic hepatitis B according to claim 1, it is characterized in that, it is to be made by the material of following weight proportioning: 7 parts of Radix Scrophulariaes, 13 parts of Rhizoma Zingiberiss, 22 parts of Fructus Corni, 15 parts of Radix Platycodoniss, 21 parts of Rhizoma Coptidis, 13 parts of Flos Chrysanthemis, 28 parts of Herba Solidaginiss, 11 parts of Semen Hyoscyamis, 17 parts, Herba Ephedrae, 24 parts of Folium Pyrrosiaes, 27 parts of Rhizoma Polygoni Cuspidati, 18 parts of Radix Morindae Officinaliss, 17 parts of Herba Chelidoniis, 23 parts of Rhizoma Imperataes, 21 parts of Fructus Xanthii, 16 parts of Fructus Phyllanthis, 16 parts of Folium Et Cacumen Murrayae, 17 parts of Semen Pharbitidiss, 19 parts of Herba Inulae, 15 parts of Herba Sarcandraes, 14 parts of Herba Clinopodii, 21 parts of Folium Sennae, 11 parts of Radix seu Herba Gei aleppici, 13 parts of Radix Rhapontici, 23 parts of Folium Rhododendri Daurici, 24 parts of Herba Potentillae Discoloris, 14 parts of Calyx Seu Fructus Physaliss, 25 parts of Cortex Mori, 26 parts of Herba Eupatorii Lindleyanis, 24 parts, 16 parts of Radix Curcumaes and Semen Persicae.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310108674.9A CN103191386B (en) | 2013-03-22 | 2013-03-22 | Medicament for treating chronic hepatitis B |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310108674.9A CN103191386B (en) | 2013-03-22 | 2013-03-22 | Medicament for treating chronic hepatitis B |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103191386A CN103191386A (en) | 2013-07-10 |
| CN103191386B true CN103191386B (en) | 2014-04-30 |
Family
ID=48714319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310108674.9A Expired - Fee Related CN103191386B (en) | 2013-03-22 | 2013-03-22 | Medicament for treating chronic hepatitis B |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103191386B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108096307B (en) * | 2014-06-04 | 2021-02-05 | 苏州大学 | Application of lindley eupatorium herb ethanol extract in preparing anti-hepatitis B virus medicine |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1304753A (en) * | 2000-12-01 | 2001-07-25 | 张志祥 | Ganlu pill and its preparing process |
| CN1314169A (en) * | 2000-12-26 | 2001-09-26 | 陈玉周 | Medicine for treating hepatitis B |
| CN101773656A (en) * | 2009-01-09 | 2010-07-14 | 苏州知微堂生物科技有限公司 | Anti-hepatitis B nanometer Chinese medicine and production method thereof |
| CN102048940A (en) * | 2009-11-05 | 2011-05-11 | 天津太平洋制药有限公司 | Chinese medicinal preparation for treating chronic hepatitis and preparation method thereof |
-
2013
- 2013-03-22 CN CN201310108674.9A patent/CN103191386B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1304753A (en) * | 2000-12-01 | 2001-07-25 | 张志祥 | Ganlu pill and its preparing process |
| CN1314169A (en) * | 2000-12-26 | 2001-09-26 | 陈玉周 | Medicine for treating hepatitis B |
| CN101773656A (en) * | 2009-01-09 | 2010-07-14 | 苏州知微堂生物科技有限公司 | Anti-hepatitis B nanometer Chinese medicine and production method thereof |
| CN102048940A (en) * | 2009-11-05 | 2011-05-11 | 天津太平洋制药有限公司 | Chinese medicinal preparation for treating chronic hepatitis and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103191386A (en) | 2013-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105535004A (en) | Application of anemoside B4 serving as EV71 virus inhibitor in preparing hand-foot-and-mouth disease resisting drugs | |
| CN103933468A (en) | Traditional Chinese medicine for treating acute pancreatitis | |
| CN102397372A (en) | Medicinal composition and pharmaceutical preparation and application thereof to treating irritable bowel syndrome | |
| CN104645132A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy, preparation method, traditional Chinese medicine preparation and application of traditional Chinese medicine composition | |
| CN108853433A (en) | A kind of Chinese medicine and preparation method thereof for treating diabetic nephropathy | |
| CN102657736B (en) | Medicament composition for treating rheumatoid arthritis and preparation method of medicament composition | |
| CN103191386B (en) | Medicament for treating chronic hepatitis B | |
| CN1969940A (en) | Antivirus pharmaceutical composition | |
| CN105288513A (en) | Traditional Chinese medicine composition for treating hepatitis B and cirrhosis | |
| CN104857436A (en) | Chinese herbal compound composition with anti-hepatoma activity as well as preparation method and application of Chinese herbal compound composition | |
| CN103893502A (en) | Traditional Chinese medicine for treating phlyctenular conjunctivitis | |
| CN104721508B (en) | A kind of pharmaceutical composition and preparation method for treating the infection of the upper respiratory tract | |
| CN103800736B (en) | A kind of pharmaceutical composition treating hypertensive nephropathy and application thereof | |
| CN102488851B (en) | Drug for treating recurrent genital herpes and preparation method thereof | |
| CN103191385B (en) | Medicament for treating infantile asthma | |
| CN101375962B (en) | Formulation for activating blood and freeing collateral vessels and preparation method thereof | |
| CN103505500B (en) | A kind of Chinese medicine composition for the treatment of hepatitis B and preparation method thereof | |
| CN111375036B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application thereof | |
| CN103285336B (en) | Chinese medicinal preparation for treating aplastic anemia | |
| CN102579909B (en) | Medicament for treating chronic hepatitis | |
| CN106492064A (en) | A kind of Chinese medicinal granule for treating children's bacterial infection diarrhoea | |
| CN105641168A (en) | Medicine for treating viral hepatitis B and viral hepatitis C and preparation method of medicine | |
| CN103142956A (en) | Medicine for treating viral myocarditis | |
| CN104689246B (en) | A kind of medicine for the treatment of gastric cancer | |
| CN105521026A (en) | Injection for treating epidemic cerebrospinal meningitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: LIU XIAOYAN Free format text: FORMER OWNER: YUE WEIZHEN Effective date: 20140327 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Liu Xiaoyan Inventor before: Yue Weizhen |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 272501 JINING, SHANDONG PROVINCE TO: 266033 QINGDAO, SHANDONG PROVINCE Free format text: CORRECT: INVENTOR; FROM: YUE WEIZHEN TO: LIU XIAOYAN |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20140327 Address after: Qingdao City People's Road No. 4 266033 Shandong Haici medical group of hepatobiliary diseases Applicant after: Liu Xiaoyan Address before: 272501 Shandong province Dehui Wenshang County Road No. 2 Applicant before: Yue Weizhen |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140430 Termination date: 20150322 |
|
| EXPY | Termination of patent right or utility model |